

Prof. Dr. YEŞİM ERALP

Kişisel Bilgiler

E-posta: Yesim.Eralp@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/Yesim.Eralp>

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0001-9603-4755

Publons / Web Of Science ResearcherID: AAD-7194-2020

Eğitim Bilgileri

Tıpta Yandal Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye 1998 - 2001

Tıpta Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye 1992 - 1998

Akademik Unvanlar / Görevler

Doç. Dr., İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2004 - 2009

Uzman, İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2001 - 2005

Uzman, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1992 - 1997

Öğretim Görevlisi Dr., İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1985 - 1991

Akademik İdari Deneyim

İstanbul Üniversitesi, 2006 - 2010

Verdiği Dersler

Yüksek Lisans

OVER TÜMÖRLERİ, Yüksek Lisans, 2016 - 2017

Lisans

TÜMÖR İMMÜNOLOJİSİ VE İMMÜNOTERAPİ, Lisans, 2016 - 2017

5. SINIF ONKOLOJİ UYGULAMA, Lisans, 2016 - 2017

HEDEFE YÖNELİK İMMUN ve GEN TEDAVİDE TEMEL İLKELER, Lisans, 2016 - 2017

ONKOLOJİDE HEDEFE YÖNELİK TEDAVİ, Lisans, 2016 - 2017

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer**
Mahidin E. I. B. M., Im S., Rihani J., Chung W., Babu K. G., Bowles J., Alfaro T. D., Wu J., Gao M., Slimane K., et al.
Journal of Clinical Oncology, cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded)
- II. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-**

small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Cicin I., Paydas S., Cilbir E., Sakalar T., Uysal M., et al.
MEDICINE, cilt.103, sa.21, 2024 (SCI-Expanded)

- III. **Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?**
Guner G., Aktas B. Y., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., ERMAN M., Yumuk P. F., Senler F. C., Cakar B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded)
- IV. **Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review**
ERALP Y., Ates U.
Vaccines, cilt.11, sa.10, 2023 (SCI-Expanded)
- V. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**
DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., KORKMAZ T., Gokmen E., ŞENER C., AYDINER A., et al.
CANCERS, sa.6, 2023 (SCI-Expanded)
- VI. **Lung Cancer in Turkey**
KAYI CANGIR A., Yumuk P. F., SAK S., AKYÜREK S., ERALP Y., Yilmaz U., Selek U., EROĞLU A., TATLI A. M., Dincbas F. O., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.17, sa.10, ss.1158-1170, 2022 (SCI-Expanded)
- VII. **Application of mRNA Technology in Cancer Therapeutics**
ERALP Y.
VACCINES, cilt.10, sa.8, 2022 (SCI-Expanded)
- VIII. **Laterality and survival in mesothelioma: A SEER database analysis.**
Parekh J., Yerlikaya A., Xie Y., Eralp Y., Adjepong Y.
JOURNAL OF CLINICAL ONCOLOGY, sa.16, 2022 (SCI-Expanded)
- IX. **International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials**
Smeltzer M. P., Scagliotti G., Wakelee H. A., Mitsudomi T., Roy U. B., Clark R. C., Arndt R., Pruett C. D., Kelly K. L., Ujhazy P., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.17, sa.5, ss.651-660, 2022 (SCI-Expanded)
- X. **Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer**
Cabioglu N., KARANLIK H., Igci A., Muslumanoglu M., TÜKENMEZ M., EMİROĞLU S., Ozkurt E., Onder S., Saip P., Eralp Y., et al.
CANCER RESEARCH, sa.4, 2022 (SCI-Expanded)
- XI. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**
AK N., Toker A., KARA M., ÖZKAN B., Ulker M., Kaba E., YEGEN G., KARAMAN Ş., Dagoglu N., Saglam E. K., et al.
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded)
- XII. **The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.**
Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded)
- XIII. **TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer**
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., Igci A., Eralp Y., AYDINER A., Saip P., et al.

BMC CANCER, cilt.21, sa.1, 2021 (SCI-Expanded)

- XIV. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients**
Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., Cicin I., Basal F. B., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.3, 2021 (SCI-Expanded)
- XV. **Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple negative breast cancer**
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoğlu M., Igci A., Eralp Y., AYDINER A., SAİP P. M., et al.
CANCER RESEARCH, sa.4, 2021 (SCI-Expanded)
- XVI. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.
LUNG CANCER, cilt.148, ss.48-54, 2020 (SCI-Expanded)
- XVII. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
Balkan medical journal, cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded)
- XVIII. **Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients**
Papadopoulou E., Tsoulos N., Tsantikidi K., Metaxa-Mariatou V., Stamou P. E., Kladi-Skandali A., Kapeni E., Tsaousis G., Pentheroudakis G., Petrakis D., et al.
PLOS ONE, cilt.14, sa.12, 2019 (SCI-Expanded)
- XIX. **Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey**
Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., Yilmaz C., TURNA Z. H., Sezer A., Cinkir H. Y., et al.
JOURNAL OF THORACIC ONCOLOGY, sa.10, 2019 (SCI-Expanded)
- XX. **The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study**
Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., SAK S., Dilege S., Tanju S., Toker A., et al.
JOURNAL OF THORACIC ONCOLOGY, sa.10, 2019 (SCI-Expanded)
- XXI. **Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center**
AK N., Toker A., Bayraktar S., ÖZKAN B., ÜLKER M. G., Dagoglu N., KARAMAN S., Kaba E., FERHATOĞLU F., AYDIN E. M., et al.
JOURNAL OF THORACIC ONCOLOGY, sa.10, 2019 (SCI-Expanded)
- XXII. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
JOURNAL OF THORACIC ONCOLOGY, sa.10, 2018 (SCI-Expanded)
- XXIII. **Possible role of stress, coping strategies, and life style in the development of breast cancer**
YILDIRIM N., ÖZKAN M., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., KALYONCU N., Izci F., Selamoglu D., Ordu C., et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, cilt.53, sa.3, ss.207-220, 2018 (SCI-Expanded)
- XXIV. **Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer**
Iyigun Z. E., Duymaz T., Ilgun A. S., Alco G., Ordu C., Sarsenov D., Aydin A. E., Celebi F. E., Izci F., Eralp Y., et al.
LYMPHATIC RESEARCH AND BIOLOGY, cilt.16, sa.1, ss.28-35, 2018 (SCI-Expanded)
- XXV. **Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients**
Ilgun S., Sarsenov D., Erdogan Z., Ordu C., Celebi F., Pilanci K. N., Ozturk A., Selamoglu D., Alco G., Aktepe F., et al.

JOURNAL OF BUON, cilt.21, sa.6, ss.1425-1432, 2016 (SCI-Expanded)

- XXVI. **Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy**
Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., ORAL E. N., KAYTAN SAĞLAM E., Saip P., Toker A., et al.
MEDICINE, cilt.95, sa.30, 2016 (SCI-Expanded)
- XXVII. **Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment**
AYDINER A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., Karanlik H., Fayda M., Kucucuk S., ÖNDER S., et al.
MEDICINE, cilt.94, sa.52, 2015 (SCI-Expanded)
- XXVIII. **The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer**
ÖZMEN V., ÖZÇINAR B., Bozdogan A., Eralp Y., YAVUZ E., DİNÇER M. Z.
EJSO, cilt.41, sa.10, ss.1368-1372, 2015 (SCI-Expanded)
- XXIX. **Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)**
Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., Dogu G. G., Eralp Y., Uslu R., Sevinc A., et al.
BREAST CANCER, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded)
- XXX. **Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?**
Pilanci K. N., Alco G., Ordu C., Sarsenov D., Celebi F., Erdogan Z., Agacayak F., Ilgun S., Tecimer C., Demir G., et al.
MEDICINE, cilt.94, sa.18, 2015 (SCI-Expanded)
- XXXI. **Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy**
GEZER U., Keskin S., Igci A., TÜKENMEZ M., Tiryakioglu D., Cetinkaya M., Disci R., Dalay N., Eralp Y.
ONCOLOGY LETTERS, cilt.8, sa.2, ss.845-848, 2014 (SCI-Expanded)
- XXXII. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?**
Karabulut S., Aksit E., Tas F., Ciftci R., Aydinler A., Yildiz İ., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.
TUMOR BIOLOGY, cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded)
- XXXIII. **Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial**
SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., Benekli M., Kucukoner M., Isikdogan A., Un O., et al.
BREAST, cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded)
- XXXIV. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded)
- XXXV. **Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer**
Eralp Y., Keskin S., YÖRÜKER E. E., Akisik E., Igci A., Muslumanoglu M., Yilmaz S., Tunaci M., Camlica H., Tuzlali S., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded)
- XXXVI. **Association of clinical and pathological variables with survival in thymoma**
AYDINER A., Toker A., Sen F., Bicakci E., KAYTAN SAĞLAM E., Erus S., Eralp Y., TAŞ F., ORAL E. N., Topuz E., et al.
MEDICAL ONCOLOGY, cilt.29, sa.3, ss.2221-2228, 2012 (SCI-Expanded)
- XXXVII. **Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain**
Altundag K., DİZDAR Ö., Ozsaran Z., Ozkok S., Saip P., Eralp Y., Komurcu S., Kuzhan O., ÖZGÜROĞLU M., Karahoca M.

Onkologie, cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded)

- XXXVIII. **Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study**
Aydiner A., Sen F., KAYTAN SAĞLAM E., Oral E. N., Eralp Y., TAŞ F., Toker A., Dilege S.
CLINICAL LUNG CANCER, cilt.12, sa.5, ss.286-292, 2011 (SCI-Expanded)
- XXXIX. **Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients**
Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., Eralp Y., Camlica H., Ustuner Z., ÖZBEK U.
JOURNAL OF BUON, cilt.16, sa.2, ss.241-246, 2011 (SCI-Expanded)
- XL. **Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy**
Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., Aydoğan F., Eralp Y., AYDINER A., Yavuz E., et al.
ONCOLOGY, cilt.81, sa.1, ss.30-38, 2011 (SCI-Expanded)
- XL1. **Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors**
Cicin I., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., Topuz E.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, cilt.146, sa.2, ss.210-214, 2009 (SCI-Expanded)
- XLII. **Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis**
Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., Yavuz E., Dincer M., KAYTAN SAĞLAM E., Topuz E.
JOURNAL OF NEURO-ONCOLOGY, cilt.93, sa.2, ss.243-251, 2009 (SCI-Expanded)
- XLIII. **Malignant Ovarian Germ Cell Tumors A Single-Institution Experience**
Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozyurt C., Tuzlali S., GÖRGÜN Ö. N. H., Topuz E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.32, sa.2, ss.191-196, 2009 (SCI-Expanded)
- XLIV. **Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.**
Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., İlhan R., Topuz E.
Tumori, cilt.95, ss.207-11, 2009 (SCI-Expanded)
- XLV. **Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger**
Eralp Y., Smith T. L., Altundag K., Kau S., Litton J., Valero V., Buzdar A., Hortobagyi G. N., Arun B.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.135, sa.1, ss.141-148, 2009 (SCI-Expanded)
- XLVI. **Factors affecting the prognosis of breast cancer patients with brain metastases**
Saip P., Cicin I., Eralp Y., Kucucuk S., Tuzlali S., Karagol H., Aslay I., Topuz E.
BREAST, cilt.17, sa.5, ss.451-458, 2008 (SCI-Expanded)
- XLVII. **Ovarian carcinoma with simultaneous breast and rectum metastases**
Derin D., Eralp Y., Guney N., ÖZLÜK M. Y., Topuz E.
Onkologie, cilt.31, sa.4, ss.200-202, 2008 (SCI-Expanded)
- XLVIII. **Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance**
Eralp Y., Sakallioğlu B., Kucucuk S., Tuzlali S., Saip P., Igci A., Muslumanoglu M., Aydinler A., Topuz E.
JOURNAL OF CLINICAL ONCOLOGY, cilt.26, sa.15, 2008 (SCI-Expanded)
- XLIX. **MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer**
Eralp Y., Derin D., ÖZLÜK M. Y., Yavuz E., Guney N., SAİP P. M., Muslumanoglu M., Igci A., Kücücük S., DİNÇER M. B., et al.
Annals of Oncology, cilt.19, sa.4, ss.669-674, 2008 (SCI-Expanded)
- L. **Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer**

GEZER U., Eralp Y., Akisik E. Z., YÖRÜKER E. E., Saip P., Topuz E., Dalay N.

CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V, cilt.1137, ss.175-179, 2008 (SCI-Expanded)

- LI. **Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer**
Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., Igci A., ÖZMEN V., Kucucuk S., Aslay I., et al.
CANCER INVESTIGATION, cilt.26, sa.7, ss.671-679, 2008 (SCI-Expanded)
- LII. **Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy**
GEZER U., Eralp Y., YÖRÜKER E. E., Akisik E. Z., Saip P., Topuz E., Dalay N.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, cilt.46, sa.3, ss.311-317, 2008 (SCI-Expanded)
- LIIL. **Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt**
Eralp Y., Saip P., Aydin Z., Berkman S., Topuz E.
GYNECOLOGIC ONCOLOGY, cilt.108, sa.1, ss.248-250, 2008 (SCI-Expanded)
- LIV. **Multifocal breast cancer in women $\leq$ 35 years old**
Litton J. K., Eralp Y., Gonzalez-Angulo A. M., Broglio K., Uyei A., Hortobagyi G. N., Ann B.
CANCER, cilt.110, sa.7, ss.1445-1450, 2007 (SCI-Expanded)
- LV. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**
KARAGÖL H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., AYDINER A., Topuz E.
Medical Oncology, cilt.24, sa.1, ss.39-43, 2007 (SCI-Expanded)
- LVI. **Women age $\leq$ 35 years with primary breast carcinoma - Disease features at presentation**
Gonzalez-Angulo A., Broglio K., Kau S., Eralp Y., Erlichman J., Valero V., Theriault R., Booser D., Buzdar A., Hortobagyi G., et al.
CANCER, cilt.103, sa.12, ss.2466-2472, 2005 (SCI-Expanded)
- LVII. **Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer**
Oral E., Aydinler A., Eralp Y., Topuz E.
MEDICAL ONCOLOGY, cilt.22, sa.4, ss.367-374, 2005 (SCI-Expanded)
- LVIII. **Thymidine labeling index: Prognostic role in breast cancer**
Bilir A., Eralp Y., CABIOĞLU N., Agizhali B., Camlica H., Aydinler A.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.27, sa.4, ss.400-406, 2004 (SCI-Expanded)
- LIX. **Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation**
Gonzalez-Angulo A. M., Broglio K., Eralp Y., Kau S., Erlichman J., Valero V., Booser D., Buzdar A. U., Hortobagyi G. N., Arun B.
ANNALS OF ONCOLOGY, cilt.15, ss.58, 2004 (SCI-Expanded)
- LX. **Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model**
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
BREAST CANCER RESEARCH, cilt.6, sa.4, 2004 (SCI-Expanded)
- LXI. **Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer**
Topuz E., Eralp Y., Saglam S., Saip P., Aydinler A., Berkman S., Yavuz E.
GYNECOLOGIC ONCOLOGY, cilt.92, sa.1, ss.147-151, 2004 (SCI-Expanded)
- LXII. **Prognostic factors in localized soft-tissue sarcomas.**
Kaytan E., Yaman F., Cosar R., Eralp Y., Saip P., Darendeliler E.
American journal of clinical oncology, cilt.26, ss.411-5, 2003 (SCI-Expanded)
- LXIII. **Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).**
Alici S., Saip P., Eralp Y., Aydinler A., Topuz E.
American journal of clinical oncology, cilt.26, sa.4, ss.358-62, 2003 (SCI-Expanded)
- LXIV. **Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine**

cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydinler A., Dincer M., Aslay I., Topuz E.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded)

- LXV. **Prognostic factors in localized aggressive non-Hodgkin's lymphoma**
Alici S., Bavbek S. E., Kaytan E., Eralp Y., Onat H.
American Journal of Clinical Oncology: Cancer Clinical Trials, cilt.26, sa.1, ss.1-5, 2003 (SCI-Expanded)
- LXVI. **Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.**
Eralp Y., Saip P., Sakar B., Tas F., Aydinler A., Topuz E.
European journal of gynaecological oncology, cilt.24, sa.3-4, ss.323-6, 2003 (SCI-Expanded)
- LXVII. **Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group**
Eralp Y., Aydinler A., Kizir A., Kaytan E., Oral E., Topuz E.
CANCER INVESTIGATION, cilt.21, sa.5, ss.737-743, 2003 (SCI-Expanded)
- LXVIII. **Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: Treatment, outcome, and prognostic factors**
Alici S., Bavbek S. E., Kaytan E., Başaran M., Eralp Y., Onat H.
American Journal of Clinical Oncology: Cancer Clinical Trials, cilt.25, sa.5, ss.502-508, 2002 (SCI-Expanded)
- LXIX. **Anemia in oncology practice: Relation to diseases and their therapies**
TAŞ F., Eralp Y., BAŞARAN M., ŞAKAR B., Alici S., Argon A., Bulutlar G., Camlica H., AYDINER A., Topuz E.
American Journal of Clinical Oncology: Cancer Clinical Trials, cilt.25, sa.4, ss.371-379, 2002 (SCI-Expanded)
- LXX. **Prognostic factors and survival in late adolescent and adult patients with small round cell tumors**
Eralp Y., Bavbek S., Başaran M., Kaytan E., Yaman F., Bilgiç B., Darendeliler E., Onat H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.25, sa.4, ss.418-424, 2002 (SCI-Expanded)
- LXXI. **Clinical characteristics of gestational trophoblastic disease at a single institute**
Alici S., Eralp Y., Saip P., Argon A., BAŞARAN M., Topuz E., AYDINER A.
Tohoku Journal of Experimental Medicine, cilt.197, sa.2, ss.95-100, 2002 (SCI-Expanded)
- LXXII. **Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study**
Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., TAŞ F., Yaman F., Dogan O., Camlica H., Onat H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.24, sa.6, ss.570-575, 2001 (SCI-Expanded)
- LXXIII. **Thymidine labeling index in epithelial ovarian cancer**
Salihoglu Y., Bilir A., Aydinler A., Erkan M., Tuzlali S., Eralp Y.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, cilt.75, sa.2, ss.171-176, 2001 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors**
Dişel U., Köse F., Bilici A., Özgüroğlu M., Sağlam S., Şeker M., Aksoy S., Tek İ., Mandel N. M., Demir G., et al.
Journal of Oncological Science, cilt.8, sa.2, ss.87-93, 2022 (Scopus)
- II. **Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**
Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., ERALP Y., Gulluoglu B. M.
TURKISH JOURNAL OF SURGERY, cilt.36, sa.2, ss.147-163, 2020 (ESCI)
- III. **Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes**
Ordu C., Pilanci K. N., Alco G., Elbuen F., Koksall U. I., Ilgun S., Sarsenov D., Aydin A. E., Ozturk A., Erdogan Z. I., et al.

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.14, sa.3, ss.173-179, 2018 (Hakemli Dergi)

- IV. **Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer**
Izci F., Sarsanov D., Erdogan Z. I., Ilgun A. S., Celebi E., Alco G., Kocaman N., Ordu C., Ozturk A., Duymaz T., et al.
EUROPEAN JOURNAL OF BREAST HEALTH, cilt.14, sa.2, ss.105-111, 2018 (Hakemli Dergi)
- V. **Roles of Biopsychosocial Factors in the Development of Breast Cancer**
ÖZKAN M., Yildirim N., Disci R., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., KALYONCU N., Izci F., Selamoglu D., et al.
EUROPEAN JOURNAL OF BREAST HEALTH, cilt.13, sa.4, ss.206-212, 2017 (Hakemli Dergi)
- VI. **The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.**
Eralp Y.
Translational oncogenomics, cilt.8, ss.1-7, 2016 (Hakemli Dergi)
- VII. **The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer**
Iyigun Z. E., Pilanci K. N., Cabuk F. K., Ilgun S., Ordu C., Duymaz T., Alco G., Celebi F., Sarsenov D., Izci F., et al.
JOURNAL OF BREAST HEALTH, sa.3, ss.119-122, 2016 (ESCI)
- VIII. **The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer**
Ordu C., McGuire K., Alco G., Pilanci K. N., Koksall U. I., Elbuken F., Erdogan Z., Agacayak F., Ilgun S., Sarsenov D., et al.
CUREUS, cilt.8, sa.6, 2016 (Hakemli Dergi)
- IX. **True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer**
Sarsenov D., Ilgun S., Ordu C., Alco G., Bozdogan A., Elbuken F., Pilanci K. N., Agacayak F., Erdogan Z., Eralp Y., et al.
CUREUS, cilt.8, sa.3, 2016 (Hakemli Dergi)
- X. **The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience**
Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., Demirci S., Icli F., Onur H., SAİP P. M., et al.
JOURNAL OF BREAST HEALTH, cilt.10, sa.4, ss.209-215, 2014 (ESCI)
- XI. **An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; report of a case with literature review.**
Alici S., Bavbek S. E., Eralp Y., Argon A., Basaran M., Aydiner A., Tuzlali S., Topuz E., Onat H.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, cilt.7, sa.4, ss.373-6, 2002 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler

- I. **Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases**
Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., Karagoz B., Yildirim Y., Karaaslan S., Guler E. N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
- II. **Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group**
Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., Molinas Mandel N., Korkmaz T., Gokmen E., Aydiner A., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri)
- III. **Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)**
Orer H. S., Nomak G., Oksuzoglu B., Senturk R., ERALP Y., Yumuk F., Nomak H., Sanyal R.
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, (Özet Bildiri)
- IV. **Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the**

treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., ÖZGÜROĞLU M., Saglam S., Seker M., AKSOY S., Tek I., Eralp Y., Mandel N. M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020,
(Özet Bildiri)

- V. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.**

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., Goksu S. S., Coskun H. S., Oyan B., Sonmez Ö., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020,
cilt.38, (Özet Bildiri)

- VI. **Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey**

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., Kostek O., Turhal S., PAYDAŞ S., Topcu S., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019,
cilt.80, (Özet Bildiri)

- VII. **Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study**

Lu Y., Malwinder S. S., Azim H., Eralp Y., Im S., Yap Y. S., Alfaro T. D., Gao M., El Saghir N. S.
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, (Özet Bildiri)

- VIII. **Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?**

Kilickap S., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., ERMAN M., Yumuk F., ÇAY ŞENLER F., Cakar B., ÇİÇİN İ., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019,
ss.637, (Özet Bildiri)

- IX. **Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study**

El Saghir N., Malwinder S., Azim H., Eralp Y., Im S., Yap Y. S., Alfaro T. D., Gao M., Lu Y.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019,
ss.140-141, (Özet Bildiri)

- X. **The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer**

Ordu C., Pilanci K. N., Elbuken F., Alco G., Koksall U. I., Ilgun S., Sarsenov D., AYDIN A. E., Ozturk A., Erdogan Z. I., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, (Özet Bildiri)

- XI. **Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients**

Elbuken F., Ordu C., Sarsenov D., Ilgun S., Pilanci K., Erdogan Z., Agacayak F., Alco G., Ozturk A., Eralp Y., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

- XII. **Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?**

Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydinler A.
20. Ulusal Cerrahi Kongresi, 2016, Antalya, Türkiye, 13 - 17 Nisan 2016, ss.1, (Tam Metin Bildiri)

- XIII. **Metaplastic breast carcinoma versus triple nevasive breast cancer survival and response to treatment**

AYDINER A., ŞEN F., ÇİFTÇİ R., RÜMEYSA Ç., ERALP Y., SAİP P. M., KARANLIK H., MERDAN F.
MEDİCİNE, 01 Aralık 2015, (Özet Bildiri)

- XIV. **Concominant Chemoradiotherapy with Etoposide Cisplatin versus Docetaxel Cisplatin in Locally Advanced Non Small Cell Lung Cancer**
ERALP Y., ŞEN F., MAKBULE T., ÖZKAYA K., BERKER Ö., ORAL E. N., KAYTAN SAĞLAM E., FIRAT P., SAİP P. M., TOKER S. A., et al.
NSCLC, 09 Eylül 2015
- XV. **Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients**
ORDU Ç., ALÇO G., KN P., S, İ., D, S., F, Ç., Zİ E., F, A., DEMİR G., ERALP Y., et al.
European Cancer Congress, 01 Eylül 2015, cilt.322, (Özet Bildiri)
- XVI. **Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment**
G, A., ORDU Ç., D, S., F, Ç., ERDOĞAN Z., AĞACAYAK F., S, İ., TECİMER C., DEMİR G., ERALP Y., et al.
EUR J SUR ONCOL, 01 Mayıs 2015, cilt.94, (Özet Bildiri)
- XVII. **Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilir?**
Karanlık H., Özgür İ., Fayda M., Yavuz E., Mudun A., Saip P. M., Eralp Y., Kurul S.
19. Ulusal Cerrahi Kongresi, Antalya, Türkiye, 16 - 20 Nisan 2014, ss.1-1751, (Tam Metin Bildiri)
- XVIII. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., Aydiner A., Topuz E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri)
- XIX. **Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model**
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
27th Annual Charles A Colman San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2004, cilt.88, (Özet Bildiri)

Etkinlik Organizasyonlarındaki Görevler

Arıkan A. E., Uras C., Bese F. N., Eralp Y., Arıbal M. E., Taşkın F., DÜLGEROĞLU O., OYAN ULUÇ B., YÜCEL S., Breastanbul 2024, Bilimsel Kongre / Sempozyum Organizasyonu, İstanbul, Türkiye, Ekim 2024

Molinas Mandel N., Oyan Uluç B., Arıbal M. E., Beşe N., Çelik L., Esen İçten G., Uras C., ERALP Y., 16. Meme Kanseri Yeni Yaklaşımlar, Bilimsel Kongre / Sempozyum Organizasyonu, İstanbul, Türkiye, Ocak 2024

Arıkan A. E., Eralp Y., Güler S. A., Kivılcım T., Korkmaz T., Sönmez Ö., Yücel S., Meme Kanseri Atölye Çalışması, Bilimsel Kongre / Sempozyum Organizasyonu, İstanbul, Türkiye, Mayıs 2023

Arıkan A. E., Korkmaz T., Eralp Y., Sönmez Ö., Yücel S., Güler S. A., Kivılcım T., Meme Kanseri Atölye Çalışması, Bilimsel Kongre / Sempozyum Organizasyonu, İstanbul, Türkiye, Aralık 2022

Metrikler

Yayın: 104
Atıf (WoS): 1298
Atıf (Scopus): 1024
H-İndeks (WoS): 20
H-İndeks (Scopus): 20

Kongre ve Sempozyum Katılımı Faaliyetleri

Karadeniz Onkoloji Günleri, Panelist, Trabzon, Türkiye, 2024
Breastanbul, Davetli Konuşmacı, İstanbul, Türkiye, 2024
On Targeted Master Oncology, Oturum Başkanı, İstanbul, Türkiye, 2024
Bahrein Meeting 23 September, Davetli Konuşmacı, Badiyah, Bahreyn, 2024
8. Jinekolojik Onkoloji Sempozyumu, Davetli Konuşmacı, İstanbul, Türkiye, 2024
İç Hastalıkları Kongresi , Davetli Konuşmacı, İstanbul, Türkiye, 2024
Uludağ Meme Kanseri Sempozyumu, Davetli Konuşmacı, Bursa, Türkiye, 2024
2. Onkolojide Yenilikler Sempozyumu, Davetli Konuşmacı, Girne, Kıbrıs (Kktc), 2024
On Targeted Master Oncology Moleküler Onkoloji, Oturum Başkanı, Ankara, Türkiye, 2024
11. Türk Tıbbi Onkoloji Kongresi, Davetli Konuşmacı, Girne, Kıbrıs (Kktc), 2024
Hedef Kanseri, Oturum Başkanı, Girne, Kıbrıs (Kktc), 2024
7.Karadeniz Meme Kongresi, Davetli Konuşmacı, Samsun, Türkiye, 2024
Temel Bilimlerden Klinik Bilimlere Araştırma Toplantıları, Davetli Konuşmacı, İstanbul, Türkiye, 2024
4. Meme Kanseri Sempozyumu, Davetli Konuşmacı, İstanbul, Türkiye, 2024
16. Meme Kanseri Yeni Yaklaşımlar Eğitim Toplantısı, Davetli Konuşmacı, İstanbul, Türkiye, 2024